Unanswered questions on the use of biologics in pediatric asthma

• Published in: The World Allergy Organization journal Vol. 16; no. 11; p. 100837
• Main Authors: Nieto, Antonio, El-Sayed, Zeinab A., Gómez, René Maximiliano, Hossny, Elham, Jiu-Yao, Wang, Kalayci, Ömer, Morais-Almeida, Mário, Phipatanakul, Wanda, Pitrez, Paulo Marcio, Pozo Beltrán, César Fireth, Xepapadaki, Paraskevi, Papadopoulos, Nikolaos G.
• Format: Journal Article
• Language: English
• Published: Milwaukee Elsevier Inc 01.11.2023; Elsevier BV; Elsevier
• Subjects: Anaphylaxis; Asthma; Benralizumab; Biological products; Biologics; Biomarkers; Childhood; Childrens health; Clinical trials; Drug dosages; Dupilumab; FDA approval; Mepolizumab; Omalizumab; Patient satisfaction; Pediatrics; Severe childhood asthma; Steroids; Tezepelumab; Tezepelumab; Benralizumab; Biologics; Omalizumab; Severe childhood asthma; Mepolizumab; Dupilumab
• ISSN: 1939-4551; 1939-4551
• DOI: 10.1016/j.waojou.2023.100837

The emergence of biologic therapies for the management of asthma has been a revolutionary change in our capacity to manage this disease. Since the launch of omalizumab, several other biologics have been marketed or are close to being marketed, suggesting that a plethora of monoclonal antibodies can be expected in the coming years. This will facilitate the transition to the paradigm of personalized medicine, but on the other hand will decisively further complicate the choice of the most appropriate treatment, in the absence of reliable enough biological markers. For these reasons, along with the relatively short time of use with these treatments, there are recurrently arising questions for which there are not even moderately documented answers, and for which the only solution must be based, with all reservations, on the combination of indirect evidence and expertise. In this paper, we attempt to address such questions, providing relevant commentaries and considering the whole width of the evidence base.